

## References

### I-116

1. Quattrocchi E, Ostegaard M, Taylor PC, et al. Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials. *PLoS ONE* 11(6):e0157961.
2. Laurenti L, Innocenti I, Autore F, et al. New developments in the management of chronic lymphocytic leukemia: role of ofatumumab. *OncoTargets and Therapy*. 2016;421-429.
3. MICROMEDEX. DrugDex Compendium®. 2021. Ofatumumab (Arzerra).
4. Clinical Pharmacology™ [database online]. 2021. Tampa FL: Gold Standard, Inc. Ofatumumab.
5. ARZERRA® (ofatumumab) [package insert]. East Hanover, NJ. Novartis Pharmaceuticals Corporation: 2009, revised 08/2016.
6. Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. *Blood*. 2016;127(2):208-215.
7. Wu Y, Wang Y, Gu Y, et al. Safety and efficacy of Ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis. *Hematology*. 2017;22(10):578-584.
8. Hillmen P, Janssens A, Babu KG, et al. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL. *Acta Oncol*. 2016:1-6.
9. Osterborg A, Udvardy M, Zaritskey A, et al. Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. *Leuk Lymphoma*. 2016;57(9):2037- 2046.
10. ARZERRA® (ofatumumab) injection, for intravenous use [package insert]. Novartis Pharmaceuticals Corporation East Hanover, New Jersey. Revised 08/2016.
11. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: The ORCHARRD Study. *Journal of Clinical Oncology*. 2017;35(5):544-551.
12. Barrientos JC, O'Brien S, Brown JR, et al. Improvement in parameters of hematologic and immunologic function and patient well-being in the Phase III RESONATE study of ibrutinib versus ofatumumab in patients with previously

- treated chronic lymphocytic leukemia/small lymphocytic lymphoma. *Clinical Lymphoma, Myeloma & Leukemia*. 2018;18(12):803.
13. van Oers M, Smolej L, Petrini M, et al. Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: Final analysis of the PROLONG study. *Blood cancer journal*. 2019;9(12):98.
  14. National Comprehensive Cancer Network (NCCN). Ofatumumab (Arzerra). NCCN Drugs and Biologics Compendium®. 2021.